Nano-dose melatonin (0.1-0.3mg) produces optimal BACE1 suppression and antioxidant effects without disrupting endogenous rhythm amplitude. At these concentrations, melatonin preferentially suppresses BACE1 transcription through MT1/ERK1/2 signaling and activates Nrf2 for antioxidant response without circadian phase-shifting effects observed at higher doses. The high-affinity MT1 receptor state is saturated at these doses while preserving endogenous rhythm amplitude. This represents the most mechanistically coherent hypothesis with strong safety profile. Development should focus on Nrf2 biomarker validation rather than circadian endpoints.
Curated pathway from expert analysis
flowchart TD A["Nano-dose Melatonin (0.1-0.3 mg)"] B["MT1 Receptor Activation (High-Affinity State)"] C["ERK1/2 Signaling Pathway"] D["Nrf2 Antioxidant Pathway Activation"] E["BACE1 Transcription Suppression"] F["Reduced Amyloid Beta and Oxidative Stress"] G["Neuroprotection"] H["Endogenous Rhythm Amplitude Preserved"] I["Nrf2 Biomarker Validation"] A --> B B --> C B --> D C --> E D -.->|"Selective activation\nno phase-shifting"| H E --> F D --> F
No linked papers recorded for this hypothesis yet.
No curated PDB or AlphaFold mapping for MT1 yet. Search RCSB →
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for MT1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No resource usage or linked notebooks recorded for this hypothesis yet.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If ultra-low physiological replacement dosing of melatonin precursors prevents AD-related neurodegeneration by restoring circadian MT1/MT2 signaling and reducing BACE1 expression, then long-term suppl | In early AD/MCI patients (n≥60), physiological-dose melatonin (0.3mg/night, 18 months) reduces BACE1 activity in CSF (>25% vs placebo, p<0.01), decreases CSF Aβ | — no observation — | pending | 0.72 |